Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
暂无分享,去创建一个
Ewgenij Proschak | Hanno Sjuts | Denys Pogoryelov | Franca-Maria Klingler | T. Wichelhaus | E. Proschak | H. Müller | S. Göttig | K. M. Pos | Stephan Göttig | Franca-M. Klingler | Thomas A. Wichelhaus | Denia Frank | Jenifer Cuesta-Bernal | Jasmin El-Delik | H. Florian Müller | Arno Koenigs | Klaas M. Pos | D. Pogoryelov | Denia Frank | Jenifer Cuesta-Bernal | Jasmin El-Delik | H. Sjuts | Arno Koenigs | K. M. Pos
[1] K. Li,et al. HPLC determination of captopril in human plasma and its pharmacokinetic study. , 1996, Biomedical chromatography : BMC.
[2] T. Raju. The Nobel Chronicles , 1999, The Lancet.
[3] T. Raju. The Nobel Chronicles , 2000, The Lancet.
[4] Joseph D. Kwasnoski,et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. , 2001, Journal of biomolecular screening.
[5] T. Denneberg,et al. Pharmacokinetics of oral tiopronin , 2004, European Journal of Clinical Pharmacology.
[6] Brian J Eastwood,et al. A Comparison of Assay Performance Measures in Screening Assays: Signal Window, Z' Factor, and Assay Variability Ratio , 2006, Journal of biomolecular screening.
[7] F. Niesen,et al. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.
[8] C. Bebrone. Metallo-beta-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. , 2007, Biochemical pharmacology.
[9] J. Frère,et al. Structural basis for the broad-spectrum inhibition of metallo-beta-lactamases by thiols. , 2008, Organic & biomolecular chemistry.
[10] G. Jacoby,et al. Updated Functional Classification of β-Lactamases , 2009, Antimicrobial Agents and Chemotherapy.
[11] T. Pruett. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America , 2010 .
[12] Honggang Zhou,et al. A structural view of the antibiotic degradation enzyme NDM-1 from a superbug , 2011, Protein & Cell.
[13] D. Ollis,et al. The identification of new metallo-β-lactamase inhibitor leads from fragment-based screening. , 2011, Bioorganic & medicinal chemistry letters.
[14] I. Johnson,et al. Fluorogenic cephalosporin substrates for β-lactamase TEM-1. , 2011, Analytical biochemistry.
[15] M. Eberlin,et al. A Comprehensive Review of the Pharmacodynamics, Pharmacokinetics, and Clinical Effects of the Neutral Endopeptidase Inhibitor Racecadotril , 2012, Front. Pharmacol..
[16] R. Owens,et al. Assay Platform for Clinically Relevant Metallo-β-lactamases , 2013, Journal of medicinal chemistry.
[17] K. Chou,et al. Metallo-β-lactamases: structural features, antibiotic recognition, inhibition, and inhibitor design. , 2013, Current topics in medicinal chemistry.
[18] R. Owens,et al. Chromophore‐Linked Substrate (CLS405): Probing Metallo‐β‐Lactamase Activity and Inhibition , 2013, ChemMedChem.
[19] Taiyi Wang,et al. Simplified captopril analogues as NDM-1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.
[20] H. Shi,et al. Engineering the stereochemistry of cephalosporin for specific detection of pathogenic carbapenemase-expressing bacteria. , 2014, Angewandte Chemie.
[21] N. Strynadka,et al. Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance , 2014, Nature.